Absence of p53 gene mutations in cutaneous melanoma.

Mutations in the p53 tumor suppressor gene are a common finding in many human malignancies. These mutations have been shown to inactivate the p53 protein and sometimes confer an oncogenic potential to the mutated gene. Type and pattern of p53 mutations may give clues to the tumor etiology, for example, ultraviolet-induced CC-->TT and C-->T transitions. Genomic DNA of 16 primary cutaneous melanomas of the superficial and nodular subtype and six melanoma metastases were screened for the presence of mutations in exons 5 to 8 of the p53 tumor suppressor gene, using the polymerase chain reaction and single-strand conformation polymorphism analysis, followed by direct DNA sequencing. We detected no mutations in any of the primary and metastatic melanomas in exons 5 to 8 of the p53 tumor suppressor gene. This indicates that, in contrast to skin carcinomas, p53 mutations are not operative in the evolution of human melanoma.

[1]  S. Tornaletti,et al.  The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. , 1993, Oncogene.

[2]  M. Barbareschi,et al.  p53 Protein expression in nevi and melanomas. , 1993, Archives of dermatology.

[3]  D. Barnes,et al.  p53 immunoreactivity in human malignant melanoma and dysplastic naevi , 1993, The British journal of dermatology.

[4]  N. Lassam,et al.  Overexpression of p53 is a late event in the development of malignant melanoma. , 1993, Cancer research.

[5]  M. Stratton,et al.  Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. , 1993, Oncogene.

[6]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[7]  N. Lassam,et al.  Expression of p53 in dysplastic nevi and malignant melanoma: 339 , 1993 .

[8]  M. Kripke,et al.  Analysis of the protective effect of different sunscreens on ultraviolet radiation-induced local and systemic suppression of contact hypersensitivity and inflammatory responses in mice. , 1993, The Journal of investigative dermatology.

[9]  D. Lane,et al.  p53 protein expression in benign and malignant skin tumours , 1993, The British journal of dermatology.

[10]  P. Nowell,et al.  Cytogenetics of melanocytic tumors. , 1993, The Journal of investigative dermatology.

[11]  R. Lothe,et al.  No germline TP53 mutations detected in familial and bilateral testicular cancer , 1993 .

[12]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[13]  A. Albino.  The role of oncogenes and growth factors in progressive melanoma-genesis. , 2008, Pigment cell research.

[14]  M. Skolnick,et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.

[15]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[16]  L. Akslen,et al.  Expression of p53 protein in cutaneous melanoma , 1992, International journal of cancer.

[17]  D. Lane,et al.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient , 1992, The Lancet.

[18]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[19]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[20]  N. Tsuchida,et al.  Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. , 1992, Oncogene.

[21]  R. Metcalf,et al.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.

[22]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[23]  P. Kleihues,et al.  p53 mutations in nonastrocytic human brain tumors. , 1991, Cancer research.

[24]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Harris,et al.  Expression of mutant p53 in melanoma. , 1991, Cancer research.

[26]  R. Metcalf,et al.  Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. , 1991, Cancer research.

[27]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[28]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[29]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[31]  J. Marks,et al.  Genetic basis for p53 overexpression in human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  U. Schlegel,et al.  Mutational analysis of the human p53 gene in malignant melanoma. , 1991, Pigment cell research.

[33]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[35]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[36]  D. Housman,et al.  Genetics of melanoma. , 1990, Cancer surveys.

[37]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[38]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[39]  L. J. Veer,et al.  N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.

[40]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[41]  A. Levine,et al.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 , 1983, Molecular and cellular biology.

[42]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.